FDA OKs New Eli Lilly Alzheimer’s Drug 

Recent FDA approval paves the way for doctors to prescribe a new drug, donanemab, under the brand name Kisunla, by Eli Lilly, for the treatment of Alzheimer’s disease. This monoclonal antibody infusion helps remove amyloid plaque buildups associated with the disease. The drug has shown promising results in slowing mental decline in patients with early-stage Alzheimer’s. Despite potential risks, such as brain swelling and bleeding, an FDA advisory panel deemed the benefits outweigh the risks. With treatment costs varying based on duration, Medicare coverage can potentially offset the expenses for over 98% of patients.